A Phase 1, Randomized, Double-blind (Sponsor-open), Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06667272 Under Fed And Fasted Conditions, In Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized, Double-blind (Sponsor-open), Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06667272 Under Fed And Fasted Conditions, In Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs PF 06667272 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Oct 2017 Status changed from recruiting to completed.
    • 02 Sep 2017 Planned End Date changed from 31 Aug 2017 to 5 Sep 2017.
    • 02 Sep 2017 Planned primary completion date changed from 31 Aug 2017 to 5 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top